Advertisements


Iovance Biotherapeutics provides clinical update on C-144-01, C-145-04

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results

WARREN, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the thi.....»»

Category: earningsSource: benzingaNov 7th, 2018

Mid-Day Market Update: EXFO Falls After Q4 Results; Iovance Biotherapeutics Shares Climb

Midway through trading Friday, the Dow traded up 0.80 percent to 25,252.55 while the NASDAQ climbed 1.82 percent to 7,462.44. The S&P also rose, gaining 1.14 percent to 2,759.37. read more.....»»

Category: blogSource: benzingaOct 12th, 2018

Iovance Biotherapeutics announces clinical trial updates with collaborators

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 16th, 2018

Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results

WARREN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today prov.....»»

Category: earningsSource: benzingaMay 10th, 2018

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript)

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript).....»»

Category: topSource: seekingalphaApr 6th, 2019

Immutep (IMMP) To Host Eftilagimod Alpha Clinical Development Update Global - Slideshow

Immutep (IMMP) To Host Eftilagimod Alpha Clinical Development Update Global - Slideshow.....»»

Category: topSource: seekingalphaApr 5th, 2019

Iovance Biotherapeutics (IOVA) Shares Cross Above 200 DMA

In trading on Wednesday.....»»

Category: futuresSource: nasdaqApr 3rd, 2019

Merus Announces Financial Results for the Full Year 2018 and Provides Business Update

UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length hum.....»»

Category: earningsSource: benzingaApr 3rd, 2019

Iovance clinical updates strengthen investment thesis, says H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 3rd, 2019

Iovance Biotherapeutics to close IOV-LUN-201 study, add arm to IOV-COM-202 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 3rd, 2019

Iovance Biotherapeutics doses first patient in in Cohort 4 of innovaTIL-01 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2019

Iovance Biotherapeutics presents data on T-cell diversity at AACR meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 1st, 2019

TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today reported financial re.....»»

Category: earningsSource: benzingaApr 1st, 2019

Iovance Biotherapeutics management to meet with Oppenheimer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 29th, 2019

OSE Immunotherapeutics Reports 2018 Financial Results and Business Update

Four differentiated therapeutic programs progressing through clinical studies in immuno-oncology and autoimmune diseases OSE's partnership business model based on innovative products; Multiple validating partnering milestones generated €35 milli.....»»

Category: earningsSource: benzingaMar 28th, 2019

aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update

Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO, March .....»»

Category: earningsSource: benzingaMar 25th, 2019

SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update

NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the.....»»

Category: earningsSource: benzingaMar 22nd, 2019

2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets

2018 FINANCIAL RESULTS AND BUSINESS UPDATE: LANDMARK DEAL WITH ASTRAZENECA TO SUPPORT TRANSITION INTO A FULLY INTEGRATED ONCOLOGY-FOCUSED BIO.....»»

Category: earningsSource: benzingaMar 20th, 2019

CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update

MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported its financial res.....»»

Category: earningsSource: benzingaMar 18th, 2019

Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developin.....»»

Category: earningsSource: benzingaMar 14th, 2019